Y-mAbs Therapeutics, Inc. IPO Research Information

Y-mAbs Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Y-mAbs Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Y-mAbs Therapeutics, Inc.	YMAB - NASDAQ	$14.00-$16.00	$16.00	$26.50	6 million	9/21/2018
Underwriter(s): BofA Merrill Lynch, Cowen, Canaccord Genuity
Co-Manager(s): BTIG
Industry: Health Care
Filing(s): Filed 2018-08-24 Terms Added 2018-09-07

Y-mAbs Therapeutics, Inc. Quote & Chart - Click for current quote - YMAB

About Y-mAbs Therapeutics, Inc. (adapted from Y-mAbs Therapeutics, Inc. prospectus):
They are a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "YMAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.